Catalog No.
Product Name
Application
Product Information
Citations
-
Drug Impurity
Quetiapine impurity 11 is a recognized impurity associated with the antipsychotic compound Quetiapine. This chemical can be used in research applications to assess the purity and quality of pharmaceutical formulations, aiding in regulatory compliance and drug safety evaluations. Its characterization and quantification are essential for understanding the implications of impurities on drug efficacy and safety profiles. -
Drug Impurity
Fluticasone impurity 6 is a known impurity associated with Fluticasone, a corticosteroid used for its anti-inflammatory properties. This compound is relevant in analytical applications, particularly in the characterization and quality assessment of Fluticasone formulations. Its presence can impact the efficacy and safety profile of the final product, making it critical for researchers in pharmaceutical development and regulatory compliance. -
Drug Impurity
Pramipexole impurity 5, also known as Pramipexole impurity C, is a chemical impurity associated with the drug Pramipexole. As a byproduct, it is essential for quality control and characterization in pharmaceutical research. The study of this impurity contributes to the understanding of the drug's pharmacological properties and enhances assessment of its safety and efficacy. -
Drug Impurity
Fluphenazine Impurity 4 is a chemical impurity associated with the antipsychotic drug, fluphenazine. It serves as an important reference standard for the quality control and purity assessment of fluphenazine formulations. This compound is relevant for analytical research and development processes, ensuring compliance with regulatory guidelines in pharmaceutical quality assurance. -
Drug Impurity
Edoxaban impurity 12, also known as Edoxaban cyclohexane ethyl ester (S,S,S)-isomer, serves as a significant impurity in the synthesis of Edoxaban. It is primarily utilized for quality control and analytical purposes in pharmaceutical research. The identification and quantification of this impurity are critical for ensuring the safety and efficacy of Edoxaban formulations. Researchers engaged in drug development and regulatory compliance will find this compound essential for proper characterization of Edoxaban products. -
Drug Impurity
Rivastigmine impurity 9 (3-Vinylphenyl ethyl(methyl)carbamate) is identified as a drug impurity associated with Rivastigmine. This compound may be of interest for studies assessing the quality and stability of Rivastigmine formulations. Its characterization is crucial for ensuring compliance with regulatory standards in pharmaceutical development and for understanding the compound's potential effects in biological systems. -
Drug Impurity
Rosuvastatin impurity 22 is a known impurity associated with the statin drug Rosuvastatin. This compound serves as a critical reference standard for analytical testing and quality control in pharmaceutical development. Its presence can significantly affect the efficacy and safety profile of Rosuvastatin, making it essential for researchers studying drug purity and formulation stability. This impurity can be utilized for method validation and to ensure compliance with regulatory standards in pharmaceutical manufacturing. -
Drug Impurity
Duloxetine impurity 7 hydrochloride is a characterized impurity of Duloxetine hydrochloride, a selective serotonin and norepinephrine reuptake inhibitor (SNRI). This compound is used primarily for quality control and research applications related to drug development and formulation studies. Its presence in pharmaceutical formulations is critical for ensuring the purity and safety of Duloxetine-based products. -
Drug Impurity
Hydrocortisone impurity 10 is a known impurity associated with the corticosteroid hydrocortisone. Its presence is relevant in pharmaceutical development and quality control, as it can impact the safety and efficacy of hydrocortisone formulations. This compound is crucial for researchers assessing the purity of hydrocortisone and ensuring compliance with regulatory standards in drug manufacturing processes. -
Drug Impurity
Dexmedetomidine impurity 8 (N-Benzyl hydroxymedetomidine) is a recognized impurity of the sedative agent Dexmedetomidine. This compound is significant for quality control and stability testing in pharmaceutical formulations containing Dexmedetomidine. Its identification and characterization are crucial for ensuring the purity and safety of drug products in clinical and research applications. -
Drug Impurity
Irbesartan impurity 3 is a chemical impurity related to the angiotensin II receptor blocker, Irbesartan. It is commonly utilized in analytical and quality control studies to assess the purity of drug formulations. Researchers can employ this compound in method development and validation to ensure compliance with regulatory standards in pharmaceutical research. -
Drug Impurity
Fluticasone impurity 9 is a characterized impurity associated with Fluticasone. It is utilized for assessing the purity and quality of pharmaceutical formulations containing Fluticasone. Researchers can employ this impurity to study its potential effects in formulations, ensuring compliance with regulatory standards in drug development and safety evaluations. -
Drug Impurity
Linagliptin impurity 4 is a defined impurity of the DPP-4 inhibitor linagliptin. It serves as a critical reference standard for quality control during the synthesis and analysis of linagliptin. This impurity can be utilized in pharmacological studies and method development to ensure the purity and compliance of pharmaceutical preparations. -
Drug Impurity
Atorvastatin impurity 7 is a defined impurity of the cholesterol-lowering agent Atorvastatin, primarily targeting HMG-CoA reductase. This compound is important for quality control and analytical studies in pharmaceutical development. Its characterization is essential for ensuring the purity and safety of Atorvastatin formulations, making it a critical reagent in drug quality assurance and research applications. -
Drug Impurity
Rivaroxaban impurity 36 is a known impurity of the anticoagulant drug Rivaroxaban, which primarily targets factor Xa to inhibit thrombin generation. This impurity may be relevant for analytical studies and quality control during the synthesis and testing of Rivaroxaban. Research applications include method development for drug purity assessment and stability testing in pharmaceutical formulations. -
Drug Impurity
Lamivudine impurity 6, also known as lamivudine sulfoxide, serves as a significant impurity in the synthesis of Lamivudine. This compound is important for analytical and quality control studies to assess the purity of Lamivudine samples. Its identification and quantification can aid in understanding the compound's behavior and safety profiles in pharmaceutical formulations. -
Drug Impurity
Atorvastatin impurity 11 is a chemical impurity associated with the synthesis of Atorvastatin, a widely used statin for cholesterol management. This compound serves as a necessary reference standard in pharmacological studies, particularly in the evaluation of drug purity and quality control processes. Its identification and quantification are crucial for ensuring the safety and efficacy of atorvastatin formulations in clinical applications. -
Drug Impurity
Ozagrel methyl ester is a drug impurity associated with the pharmaceutical compound ozagrel, which acts as a selective thromboxane A2 synthase inhibitor. It serves as a useful reference standard in analytical chemistry for the evaluation of drug purity and stability. This compound is instrumental in research applications aimed at understanding the pharmacokinetics and safety profiles of ozagrel in various biological contexts. -
Drug Impurity
Omeprazole impurity 1 is a known impurity of the proton pump inhibitor omeprazole. It is relevant in pharmaceutical research for the characterization and analysis of omeprazole formulations. The identification and quantification of this impurity are essential for ensuring the quality and safety of omeprazole-based therapies. It serves as a valuable reference standard for method development and validation in drug analysis. -
Drug Impurity
Hydroxy O-desmethyl apixaban is a drug impurity associated with apixaban, an anticoagulant that inhibits factor Xa. This compound is critical for analytical and biochemical studies to assess drug purity and safety. Its presence and quantification are important for quality control and regulatory compliance in pharmaceutical development. -
Drug Impurity
Chlorthalidone impurity 3, also known as Chlorthalidone impurity D, is a chemical impurity related to the antihypertensive agent Chlorthalidone. It serves as a critical reagent for quality control and validation in pharmaceutical development, facilitating the assessment of drug purity and stability. This impurity may also be employed in research applications aimed at understanding the metabolic pathways and potential side effects associated with Chlorthalidone. -
Drug Impurity
Vonoprazan impurity 1 is a chemical impurity associated with the drug Vonoprazan, a potassium-competitive acid blocker. It is crucial for analytical studies and quality control during the synthesis of Vonoprazan. This impurity may be used in research to assess the purity and safety of Vonoprazan formulations. -
Drug Impurity
Trazodone impurity 16 is a known impurity associated with the antidepressant Trazodone. This compound is critical for researchers involved in drug quality control and stability studies. It is essential for understanding the metabolic profile and safety assessment of Trazodone in pharmaceutical formulations. -
Drug Impurity
Sildenafil impurity 13 is a chromatographic impurity associated with Sildenafil. It serves as an important reference standard for quality control and analytical testing in pharmaceutical research. This compound is critical for ensuring the purity and efficacy of Sildenafil formulations and is utilized in the development and assessment of drug products. -
Drug Impurity
3,4-Dibromo-2-fluoroaniline is a chemical compound primarily characterized as a drug impurity. This molecule is often encountered in the synthesis of pharmaceuticals, where it may arise during the manufacturing process. Its identification and quantification are essential for ensuring the purity and safety of drug products in compliance with regulatory standards. Analytical applications of this compound include use in impurity profiling and quality control testing within the pharmaceutical industry. -
Drug Impurity
Ranitidine impurity 11 is a known impurity associated with Ranitidine. Its presence may impact the pharmaceutical quality and efficacy of formulations containing Ranitidine. This compound is essential for analytical chemistry applications, particularly in the assessment of drug purity and stability in pharmaceutical research. -
Drug Impurity
Clozapine impurity 1 is a known impurity associated with the antipsychotic agent clozapine. This compound serves as a critical reference standard for the analysis and characterization of clozapine formulations. Its identification and quantification are essential in ensuring the quality and safety of pharmaceutical products containing clozapine. Researchers utilize this impurity for method development in stability testing and compliance with regulatory standards. -
Drug Impurity
Ciprofloxacin impurity 8 is a known impurity related to the antibiotic Ciprofloxacin. It may be utilized in analytical chemistry to help in the assessment of drug purity and stability. This compound is essential for research applications focusing on the quality control of pharmaceutical formulations containing Ciprofloxacin. Further studies may explore its potential effects and interactions in biological systems. -
Drug Impurity
Cinakase impurity 13 is a known impurity associated with the drug Cinakase. This compound serves as a critical reference standard for the analysis of drug purity and quality control in pharmaceutical research. It is utilized in various applications related to the assessment of drug formulation integrity and can aid in the development of analytical methodologies to detect impurities during the drug development process. -
Drug Impurity
Levothyroxine impurity 4 is a known impurity of the thyroid hormone replacement therapy, Levothyroxine. This compound can be utilized in analytical studies to assess the purity of Levothyroxine preparations. Its characterization is essential for ensuring the quality and safety of pharmaceutical formulations containing Levothyroxine. -
Drug Impurity
Carvedilol impurity 9 (4'-Benzyloxy carvedilol) is a known impurity of the beta-blocker Carvedilol. This compound is analyzed for its potential effects on drug efficacy and safety profiles during pharmaceutical development. It is relevant for studies assessing the purity of Carvedilol formulations and understanding the implications of impurities in drug performance. -
Drug Impurity
14,15-Dehydro budesonide is a drug impurity with implications in pharmacological research. It serves as a valuable reference standard for analytical studies assessing the purity of budesonide formulations. The presence of this compound can impact the evaluation of drug efficacy and safety, making it essential for quality control in pharmaceutical development. -
Drug Impurity
Terbinafine impurity 9 is a known impurity associated with the antifungal compound Terbinafine. This compound can serve as a critical reference standard for quality control and analytical testing in pharmaceutical development. Its characterization is essential for assessing the purity and compliance of Terbinafine formulations, enabling more accurate evaluations in drug development and safety assessments. -
Drug Impurity
Sertraline impurity 7, also known as rac-cis-3,4-Deschlorosertraline, is a chemical impurity associated with the selective serotonin reuptake inhibitor (SSRI) Sertraline. This compound is significant for research into the safety and efficacy of Sertraline as well as its metabolites. It may be utilized in analytical studies to assess the purity of pharmaceutical formulations and to understand the implications of impurities in pharmacological profiles. -
Drug Impurity
Montelukast impurity 2 ((S)-MK0476) is a characterized impurity of the leukotriene receptor antagonist Montelukast. It serves as a critical reference standard for quality control and stability testing in pharmaceutical formulations. This compound is essential for studies focusing on the synthesis and purification processes related to Montelukast, ensuring compliance with regulatory standards in drug manufacturing. -
Drug Impurity
Dabigatran impurity 45 is a chemical impurity associated with the anticoagulant agent Dabigatran. It is primarily utilized as a reference standard for analytical characterization and quality control in pharmaceutical research. This impurity is important for ensuring the safety and efficacy of Dabigatran formulations in drug development and compliance testing. -
Drug Impurity
Dexamethasone impurity 4 is a known impurity associated with Dexamethasone. This compound is primarily used in quality control and analytical chemistry to assess the purity of Dexamethasone formulations. It serves as a reference standard for method validation and helps ensure compliance with regulatory requirements in pharmaceutical development and manufacturing. -
Drug Impurity
Ondansetron impurity 4 is a chemical impurity associated with the pharmaceutical compound Ondansetron. It serves as an important reference standard in the quality control and assessment of drug formulations. This impurity can be utilized in analytical applications to ensure the purity and safety of Ondansetron-based medications, contributing to the understanding of its chemical profile in pharmaceutical research. -
Drug Impurity
Terbinafine impurity 3 is a known impurity of the antifungal agent terbinafine, primarily associated with its synthesis and pharmacological assessment. Its characterization and evaluation are essential for ensuring the purity and quality of terbinafine in pharmaceutical formulations. This impurity can be utilized in compliance studies and to elucidate the metabolic pathways of terbinafine in various biological systems. -
Drug Impurity
Ciprofloxacin impurity 1, also known as Ciprofloxacin impurity C, is a known impurity of the antibiotic Ciprofloxacin. This compound is primarily utilized in pharmaceutical research for the assessment of drug purity and quality control in ciprofloxacin formulations. Its presence in drug samples offers important insights into the synthesis and stability of ciprofloxacin, making it essential for regulatory compliance and safety evaluations in drug development. -
Drug Impurity
Methylprednisolone acetate impurity 7 is a recognized impurity associated with the corticosteroid Methylprednisolone acetate. This compound serves as a critical reference standard in pharmacological and analytical research, particularly in ensuring the purity and quality of pharmaceutical formulations. Its characterization can aid in the assessment of drug stability, efficacy, and safety profiles in various biological systems. -
Drug Impurity
(S)-2-Amino-3-(4-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenoxy)-3,5-diiodophenyl)propanoic acid serves as a drug impurity relevant to the characterization and quality control of Levothyroxine. This compound can be employed in analytical studies to identify and quantify impurities within pharmaceutical formulations. Its presence may impact the efficacy and safety of Levothyroxine, making it valuable for researchers engaged in drug development and compliance testing. -
Drug Impurity
6-Chloroconazole impurity 17 is a known impurity of the antifungal agent 6-Chloroconazole. Its identification is crucial for quality control and regulatory compliance in pharmaceutical formulations. This compound serves as a reference standard for analytical techniques, aiding in the evaluation of drug purity and stability in chemical research and development. -
Drug Impurity
Domperidone impurity 2 is a known impurity associated with the pharmaceutical compound Domperidone. As a drug impurity, it is critical for ensuring the safety and efficacy of formulations containing Domperidone. Its characterization plays a significant role in quality control during drug development and regulatory assessments. This compound is essential for research focusing on the identification and quantification of impurities in pharmaceutical products. -
Drug Impurity
Carvedilol impurity 10, also known as N-Benzylcarvedilol, is a drug impurity associated with Carvedilol. Its presence in pharmaceutical formulations is significant for studying the safety, efficacy, and quality of the main compound. This impurity is essential for analytical applications, including method development and validation, ensuring compliance with regulatory standards in drug manufacturing. -
Drug Impurity
Citalopram impurity 10 is a drug impurity associated with the selective serotonin reuptake inhibitor Citalopram. This impurity serves as a critical analytical reference standard for pharmaceutical development and quality control, facilitating the assessment of Citalopram's purity and stability. Its presence in formulations underscores the importance of ensuring drug safety and efficacy through rigorous impurity profiling in pharmaceutical research. -
Drug Impurity
Apixaban impurity 15 is a specific impurity associated with the cardiovascular drug Apixaban, a selective factor Xa inhibitor. This compound is essential for quality control and analytical studies in pharmaceutical research and development, particularly in the assessment of drug purity and stability. Researchers utilize this impurity to investigate the degradation products and ensure compliance with regulatory standards. -
Drug Impurity
Buspirone impurity 5, also referred to as Buspirone impurity B, is a known impurity associated with the synthesis of Buspirone. This compound serves as a critical analytical standard for the assessment of drug purity and quality control in pharmaceutical research. Its identification and quantification are essential for ensuring the safety and efficacy of Buspirone formulations. -
Drug Impurity
Telmisartan impurity 12 is a recognized impurity of the antihypertensive agent Telmisartan. Its characterization is important for quality control in pharmaceutical development and formulation. This reagent is utilized in research to ensure the integrity and safety of Telmisartan-based therapies. -
Drug Impurity
Metoprolol impurity 6 is a chemical impurity associated with the synthesis of Metoprolol, a selective beta-1 adrenergic antagonist. This compound can be utilized in pharmaceutical research for the characterization and quantification of impurities in drug formulations. Its analysis is essential for ensuring the safety and efficacy of Metoprolol products in clinical applications.
